Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib

• Wei Jiang, MD,
• Ruting Guan, PhD,
• Yang W. Shao, PhD,
• Bo Wang, PhD,
• Yina Wang, MD

Affiliations

Wei Jiang, MD

Department of Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China

Ruting Guan, PhD

Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People’s Republic of China

Yang W. Shao, PhD

Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People’s Republic of China

Bo Wang, PhD

Department of Pathology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China

Yina Wang, MD

Department of Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; Corresponding author. Address for correspondence: Yina Wang, MD, Department of Oncology, College of Medicine, Zhejiang University Department of Oncology, First Affiliated Hospital, Hangzhou, People’s Republic of China.